American Cancer Society explainer stating that FDA has approved methylene blue for only one use (methemoglobinemia), that it is not approved or proven as a cancer treatment, and that most cancer evidence is laboratory or animal work.
The US Food and Drug Administration (FDA) has approved methylene blue for only one use. It is approved to treat methemoglobinemia.
American Cancer Society explainer stating that FDA has approved methylene blue for only one use (methemoglobinemia), that it is not approved or proven as a cancer treatment, and that most cancer evidence is laboratory or animal work. C15/C16/C9 American Cancer Society. Study type: patient-facing evidence explainer, published 15 October 2026. Country: USA. Records the off-label uses documented elsewhere in this record (vasodilatory shock, cyanide poisoning, PDT for skin conditions such as psoriasis and eczema, cancer diagnosis) and the real risks (serotonin syndrome, G6PD haemolysis, tyramine interaction, pregnancy). Bears against the source's efficacy framing and supports the 'no comprehensive evidence' element. Also filed as MTM-37 (claims C15, C8).
